A strategic alliance between TGen Drug Development (TD2) and Horizon Discovery Limited will significantly advance personalized medicine.
Almac, Merck KGaA, and the Medical Research Council, have partnered to undertake a study to assess potential biomarkers of response to cetuximab (Erbitux) using samples from the MRC COIN trial.
The study also reveals a small molecule inhibitor developed by Ferguson, which may provide a new and better way to treat anxiety, depression and other related disorders
In a step towards a possible treatment for Huntington's disease, scientists at Albert Einstein College of Medicine of Yeshiva University have shown for the first time that the accumulation of a mutated protein may explain damaging cellular behavior in Huntington's disease.
A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.
Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases.
Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms.
Researchers at IRB Barcelona have refined the process of obtaining "photographs" of highly dynamic proteins, an important step in drug design.
BioClinica, Inc., a global provider of clinical trial management services, has released BioClinica WebSend, a system that simplifies and accelerates image collection for clinical studies.
Through an in-depth understanding and innovative exploitation of material properties that are important for micro-scale experimentation, Dolomite has developed and manufactured a range of standard and customized flow cells for chemical analysis.
Abbott announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to Abbott's cash tender offer to purchase all of the outstanding shares of common stock of Facet Biotech Corporation has expired, satisfying one of the conditions necessary for the consummation of the tender offer.
Bristol-Myers Squibb Company announced that the Board of Directors has elected Charles Bancroft chief financial officer.
Tioga Pharmaceuticals, Inc. has reached an agreement with the FDA on Special Protocol Assessments (SPAs) for the Phase 3 efficacy protocols for asimadoline for patients with D-IBS.
Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to in Japan seeking approval of the anticoagulant, edoxaban, for the prevention of venous thromboembolism (VTE) after major orthopedic surgery.
Researchers have shown that a peptide called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate, and pancreatic cancers in mice.